Hostname: page-component-6bf8c574d5-mggfc Total loading time: 0 Render date: 2025-02-24T03:36:10.841Z Has data issue: false hasContentIssue false
  • English
  • Français

Discontinuation of admission screening for coronavirus disease 2019 (COVID-19) and the impact on in-hospital clusters of COVID-19: Experience at a tertiary-care center

Published online by Cambridge University Press:  24 April 2023

Hitoshi Honda Open the ORCID record for Hitoshi Honda [Opens in a new window] ,
Masataka Nakagawa ,
Rie Nisida ,
Chiyo Shintani ,
Manami Hamagishi ,
Yuki Uehara ,
Mitsunaga Iwata  and
Yohei Doi
Hitoshi Honda*
Affiliation:
Division of Infection Control, Department of Quality and Safety in Healthcare, Fujita Health University School of Medicine, Aichi, Japan Department of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan
Masataka Nakagawa
Affiliation:
Division of Infection Control, Department of Quality and Safety in Healthcare, Fujita Health University School of Medicine, Aichi, Japan
Rie Nisida
Affiliation:
Division of Infection Control, Department of Quality and Safety in Healthcare, Fujita Health University School of Medicine, Aichi, Japan
Chiyo Shintani
Affiliation:
Division of Infection Control, Department of Quality and Safety in Healthcare, Fujita Health University School of Medicine, Aichi, Japan
Manami Hamagishi
Affiliation:
Division of Infection Control, Department of Quality and Safety in Healthcare, Fujita Health University School of Medicine, Aichi, Japan
Yuki Uehara
Affiliation:
Department of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan
Mitsunaga Iwata
Affiliation:
Department of General Internal Medicine, Emergency and Critical Care Medicine, Fujita Health University School of Medicine, Aichi, Japan
Yohei Doi
Affiliation:
Department of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania, United States
*
Author for correspondence: Hitoshi Honda, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

We evaluated the impact of discontinuing universal preadmission screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) on the occurrence of nosocomial clusters of coronavirus disease 2019 (COVID-19) during the SARS-CoV-2 o (omicron) variant period. No increasing trend in nosocomial clusters was observed during community-based surges before and after discontinuation. This finding supports the safety of the practice change.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 44 , Issue 11 , November 2023 , pp. 1877 - 1880
Check for updates
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Klompas, M, Baker, MA, Rhee, C. Coronavirus disease 2019’s challenges to infection control dogma regarding respiratory virus transmission. Clin Infect Dis 2022;75:e102–e104.CrossRefGoogle ScholarPubMed
Uchida, S, Uwamino, Y, Uno, S, et al. Universal polymerase chain reaction screening for severe acute respiratory syndrome coronavirus 2 in asymptomatic patients before hospital admission in Tokyo, Japan. J Clin Virol 2021;142:104915.CrossRefGoogle ScholarPubMed
Alsuhaibani, MA, Kobayashi, T, Trannel, A, et al. Coronavirus disease 2019 (COVID-19) admission screening and assessment of infectiousness at an academic medical center in Iowa, 2020. Infect Control Hosp Epidemiol 2022;43:974–978.CrossRefGoogle ScholarPubMed
Rhee, C, Kanjilal, S, Baker, M, Klompas, M. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin Infect Dis 2021;72:1467–1474.CrossRefGoogle ScholarPubMed
Abbas, S, Yusuf, MA. Assessing the utility of universal preprocedure severe acute respiratory syndrome coronavirus 2 polymerase chain reaction testing at a cancer center. Infect Control Hosp Epidemiol 2022. doi: 10.1017/ice.2022.76.CrossRefGoogle Scholar
Lippi, G, Henry, BM, Sanchis-Gomar, F. Potential drawbacks of frequent asymptomatic coronavirus disease 2019 (COVID-19) testing. Infect Control Hosp Epidemiol 2021;42:1405–1406.CrossRefGoogle ScholarPubMed
Talbot, TR, Hayden, MK, Yokoe, DS, et al. Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: challenges and considerations. Infect Control Hosp Epidemiol 2023;44:2–7.CrossRefGoogle ScholarPubMed
Wu, Y, Kang, L, Guo, Z, Liu, J, Liu, M, Liang, W. Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis. JAMA Netw Open 2022;5:e2228008.CrossRefGoogle ScholarPubMed
Bonsignore, M, Hohenstein, S, Kodde, C, et al. Burden of hospital-acquired SARS-CoV-2 infections in Germany: occurrence and outcomes of different variants. J Hosp Infect 2022;129:82–88.CrossRefGoogle ScholarPubMed
He, X, Lau, EHY, Wu, P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26:672–675.CrossRefGoogle ScholarPubMed